指南与共识特殊人群用药抗栓抗凝管理

直接口服抗凝药在极端体重患者中的应用:文献综述与建议

Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations.
指南 / 共识 · Am J Health Syst Pharm · 2020-01-01

本文综述直接口服抗凝药(DOAC)在低体重和高体重患者中治疗静脉血栓栓塞症(VTE)及预防心源性卒中的文献,并就药物选择与剂量给出建议。结论指出,尽管证据稀疏,阿哌沙班和利伐沙班的安全性和有效性特征似乎最有利,应避免使用艾多沙班和达比加群。

要点

  • 极端体重患者使用DOAC时,阿哌沙班和利伐沙班的安全有效性特征最有利。
  • 应避免在极端体重患者中使用艾多沙班和达比加群。
  • 选择DOAC时需仔细考虑极端体重患者的安全性和有效性问题。

核心结论

  • 尽管已发表证据稀疏,阿哌沙班和利伐沙班在极端体重患者中似乎具有最有利的安全性和有效性特征,应避免使用艾多沙班和达比加群。

研究设计与样本

  • 本文为文献综述,回顾DOAC在低体重和高体重患者中治疗VTE及预防心源性卒中的文献。

主要发现

  • 临床试验尚未完全阐明低体重和高体重患者中DOAC的选择和最佳剂量。
  • 证据提示极端体重患者的安全性和有效性问题值得在选择DOAC时仔细考虑。

临床怎么用

  • 在极端体重患者中选用DOAC时,可优先考虑阿哌沙班或利伐沙班,避免使用艾多沙班和达比加群。

局限性

  • 已发表的关于极端体重患者使用DOAC的证据稀疏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the literature on treatment of venous thromboembolism (VTE) and prevention of cardioembolic stroke with direct-acting oral anticoagulants (DOACs) in low- and high-body-weight patients and to make recommendations regarding agent selection and dosing in these patient populations. SUMMARY: The selection and optimal dosing of DOACs in low- and high-body-weight patients has not yet been fully elucidated by clinical trials; however, evidence suggests that issues of both safety and efficacy in patients at the extremes of body weight may warrant careful consideration when selecting a DOAC for such patients. This review provides a thorough discussion of the use of DOACs in the treatment of VTE and prevention of cardioembolic stroke in patients at the extremes of body weight and provides guidance regarding agent selection. CONCLUSION: While the published evidence on use of DOACs in patients at extremes of body weight is sparse, apixaban and rivaroxaban appear to have the most favorable safety and efficacy profiles. Edoxaban and dabigatran should be avoided.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Covert K, Branam DL. Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Am J Health Syst Pharm. 2020. PMID: 32426845. doi:10.1093/ajhp/zxaa059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。